SAN DIEGO, Dec. 16, 2019 /PRNewswire/ -- Decipher Biosciences, a commercial stage precision oncology company initially focused on urologic cancers, today announced that recent findings from a ...
SAN DIEGO, March 24, 2020 /PRNewswire/ -- Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers, today ...
The Decipher (GenomeDX Biosciences) test differentiates men at higher risk for prostate cancer metastasis after prostatectomy from those at lower risk and adds prognostic value in comparison with ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...
Decipher test scores are independently associated with biopsy upgrades in men on active surveillance for Gleason grade group 1 prostate cancer. Higher Decipher scores on the initial test are ...
Decipher correlation patterns post prostatectomy: initial experience from 2 342 prospective patients
Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty ...
DeCipher: A Novel ChatGPT-based Service for Web3 Developers, Enabling Precise Documentation Generation from Smart Contracts DeCipher leverages advanced AI models, ChatGPT3.5 and 4, specifically ...
What is Decipher Test for Prostate Cancer? Decipher test is a transformative genomic test that evaluates the activity of genes in prostate cancer that has a high chance of progressing to advanced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results